Hypogonadism tied to impaired HDL function

  • Adorni MP & al.
  • J Clin Endocrinol Metab
  • 5 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • High-density lipoprotein (HDL) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) are altered in men with hypogonadism.

Why this matters

  • Disruptions in HDL function may help explain why patients with hypogonadism are at increased risk for CV events.

Key results

  • Patients with hypogonadism and control subjects had similar lipid profiles.
  • Patients with hypogonadism had 16.2% reduced total CEC (P<.0001 style="list-style-type:circle;">
  • 19.6% lower levels HDL ATP binding cassette transporter A1 (P=.0012).
  • 40.9% lower levels of ATP binding cassette transporter G1 (P<.0001>
  • 12.9% lower levels of aqueous diffusion-mediated CEC (P=.0128).
  • Patients with hypogonadism had 43% increased serum CLC (P<.0001 style="list-style-type:circle;">
  • 18.45 vs 15.15 μg cholesterol per milligram protein in patients with primary vs secondary hypogonadism (P=.019).
  • In patients with hypogonadism, serum CLC was inversely correlated with testosterone levels (P=.001).
  • Study design

    • 20 hypogonadal men and 17 age- and BMI-matched control participants were analyzed for HDL functional capacity.
    • Funding: IRCCS Istituto Auxologico Italiano; Fondazione Cariplo; Intramural Grant Piano Sostegno alla Ricerca; Fondazione Carlo Sirtori.

    Limitations

    • Small patient sample size.
    • HDL structure/composition not tested.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit